Table 1 Baseline characteristics.
From: FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML
Characteristic | N = 56 |
|---|---|
Female | 33 (59%) |
Median age | 50.6 |
MRD marker | |
NPM1 | 45 (80%) |
NUP98::NSD1 | 5 (8.9%) |
DEK::NUP214 | 4 (7.1%) |
CBFβ::MYH11 | 1 (1.8%) |
RUNX1::RUNX1T1 | 1 (1.8%) |
FLT3-ITD at diagnosis | 52 (93%) |
FLT3-TKD at diagnosis | 7 (14%) |
Missing | 6 |
MRC cytogenetic risk | |
Favourable | 2 (3.6%) |
Intermediate | 49 (88%) |
Cytogenetics missing or failed | 5 (8.9%) |
ELN 2017 risk | |
Favourable | 16 (29%) |
Intermediate | 26 (46%) |
Adverse | 9 (16%) |
Not able to assign | 5 (8.9%) |
Median months from diagnosis to molecular failure (IQR) | 9.2 (5.3–13.7) |
Number of prior lines of therapy | |
1 | 36 (64%) |
≥2 | 20 (36%) |
Refractory disease | 5 |
Relapse | 15 |
Previous midostaurin | 29 (52%) |
On midostaurin at time of molecular failure | 17 (30%) |
Previous allo-SCT | 17 (30%) |
In first remission | 12 |
In CR2 or at relapse | 5 |
Type of molecular failure | |
Molecular relapse | 26 (46%) |
Molecular persistence | 9 (16%) |
Molecular progression | 21 (38%) |
FLT3 inhibitor used for molecular failure | |
Gilteritinib | 38 (68%) |
Quizartinib | 7 (12%) |
Sorafenib | 11 (20%) |
